US Patent

US9079865 — Hydrazide containing nuclear transport modulators and uses thereof

Method of Use · Assigned to Karyopharm Therapeutics Inc · Expires 2032-07-26 · 6y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a compound represented by structural formula (I) and its uses, including treatment, modulation, and prevention of physiological conditions associated with CRM1 activity.

USPTO Abstract

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2584 —
U-3018 —
U-2855 —
U-2855 —
U-2584 —
U-2584 —

Patent Metadata

Patent number
US9079865
Jurisdiction
US
Classification
Method of Use
Expires
2032-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Karyopharm Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.